# US 6,730,293 B1 · Compositions and methods for treating inflammatory diseases of the skin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,293 B1
- Document ID: US6730293B1
- Status: Granted
- Kind: B1
- Application number: 09/645,689
- Filed: 2000-08-24
- Granted: 2004-05-04
- Earliest claimed: 1999-08-24
- Assignees: Cellgate, Inc.
- Inventors: Jonathan B. Rothbard; Paul A. Wender; P. Leo McGrane; Lalitha V. S. Sista; Thorsten A. Kirschberg
- Web page: https://patentgrep.com/patent/US6730293B1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/557: {the modifying agent being biotin}
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides compositions and methods for enhancing delivery of glucocorticoids and ascomycins such as hydrocortisone, cyclosporin and FK506 across into and across one or more layers of the skin for the treatment of psoriasis and other inflammatory diseases of the skin.

## Claims

### Claim 1

A conjugate that comprises a) a compound selected from the group consisting of a glucocorticoid, cyclosporin, FK506 and an ascomycin, and b) a delivery-enhancing transporter that comprises 5 to 25 arginine residues, wherein the conjugate is selected from the group consisting of structures 3, 4, 5 and 6, as follows:
wherein:
R1—X comprises the glucocorticoid, cyclosporin, FK506, or ascomycin;
X is a functional group on the glucocorticoid, cyclosporin, FK506, or ascomycin to which the remainder of the conjugate is attached;
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted;
Y is N;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter,
R4 is substituted or unsubstituted S or N;
R5 is NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
k is selected from 1 and 2; and
n an m are each 1.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the glucocorticoid is hydrocortisone.

### Claim 3 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises FK506.

### Claim 4 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises a cyclosporin.

### Claim 5 (depends on 4)

The conjugate of claim 4, the cyclosporin is cyclosporin A.

### Claim 6 (depends on 1)

The conjugate of claim 1, wherein the delivery-enhancing transporter comprises 7 to 15 arginine residues.

### Claim 7 (depends on 1)

The conjugate of claim 1, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines.

### Claim 8 (depends on 1)

The conjugate of claim 1, wherein the delivery-enhancing transporter comprises at least 5 contiguous arginines.

### Claim 9 (depends on 1)

The conjugate of claim 1, wherein the half-life of the conjugate is between 5 minutes and 24 hours upon contact with the skin.

### Claim 10 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises a releasable linker which releases the compound, in biologically active form, from the delivery-enhancing transporter after the compound has passed into and through one or more layers of the skin.

### Claim 11 (depends on 1)

The conjugate of claim 1, wherein the compound is released from the linker by solvent-mediated cleavage.

### Claim 12 (depends on 1)

The conjugate of claim 1, wherein the conjugate is stable at acidic pH but the compound is released from the delivery-enhancing transporter at physiological pH.

### Claim 13 (depends on 1)

The conjugate of claim 1, wherein X is selected from the group consisting of NH, O, S, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.

### Claim 14 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises structure 3 and R2 is methyl ethyl propyl, butyl, allyl, benzyl or phenyl.

### Claim 15 (depends on 14)

The conjugate of claim 14, wherein R2 is phenyl; k is l, and X is O.

### Claim 16 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises structure 4; R4 is S; R5 is NHR6; and R6 is hydrogen, methyl, allyl, butyl or phenyl.

### Claim 17 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises structure 4; R5 is NHR6, R6 is hydrogen, methyl, allyl, butyl or phenyl; and k is 1.

### Claim 18 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises:
wherein PH is phenyl.

### Claim 19 (depends on 1)

The conjugate of claim 1, wherein the conjugate is

### Claim 20 (depends on 1)

The conjugate of claim 1, wherein the conjugate is

### Claim 21 (depends on 1)

The conjugate of claim 1, wherein the conjugate is

### Claim 22 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises an ascomycin.

### Claim 23 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises a glucocorticoid.
